Californian start-up Latigo Biotherapeutics raises $135m Series A funding for non-opioid pain relief therapy development, including Phase 1 trial of its lead project, LTG-001.

Latigo Biotherapeutics, a Californian start-up focusing on non-opioid pain relief, has secured $135m in Series A funding led by Westlake Village BioPartners. Latigo intends to use the funds for the development of its portfolio of non-opioid pain therapies, including its lead project, LTG-001, which is in a Phase 1 trial targeting acute and chronic pain.

February 14, 2024
5 Articles

Further Reading